Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceTWST +3.84%69 Debt-to-EBITDA is -0.79 as of Jun. 2026. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $52.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Twist Bioscience ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Twist Bioscience's Debt-to-EBITDA or its related term are showing as below:
TWST'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83 Med: -0.36 Max: -0.08
Current: -0.83
During the past 10 years, the highest Debt-to-EBITDA Ratio of Twist Bioscience was -0.08. The lowest was -0.83. And the median was -0.36.
TWST's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.305
vs TWST: -0.83
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Twist Bioscience Debt-to-EBITDA Related Terms
Twist Bioscience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TWST vs BLLN, SHC, RDNT: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Twist Bioscience (TWST) has a Debt-to-EBITDA of -0.79 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Twist Bioscience. According to the industry distribution chart, Twist Bioscience ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is Twist Bioscience's Debt-to-EBITDA too high?
Twist Bioscience's current Debt-to-EBITDA is -0.79. Based on the distribution chart, Twist Bioscience ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Debt-to-EBITDA compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #999999 out of 114 companies for Debt-to-EBITDA. This places Twist Bioscience in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Twist Bioscience. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Debt-to-EBITDA is -0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.17, compared to a current price of $113.27 — trading 117.1% above its estimated fair value. The current Debt-to-EBITDA is -0.79. Twist Bioscience's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Twist Bioscience (TWST), the current Debt-to-EBITDA is -0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $113.27 is trading 117.1% above its estimated GF Value™ of $52.17.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
Debt-to-EBITDA: -0.79
GF Value™: $52.17 vs. price of $113.27 (117.1% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
